Akash Mourya | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Mr. Akash Mourya | Health and Medicine Advances | Best Researcher Award

PhD Scholar | National Institutes of Pharmaceutical Education and Research | India

Mr. Akash Mourya is a promising young pharmacologist specializing in pharmacology and toxicology, with a strong research focus on liver pathophysiology, hepatoprotective drug discovery, and molecular mechanisms underlying hepatic and pulmonary disorders. His ongoing Ph.D. work at NIPER Mohali builds on extensive preclinical and translational research conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, where he has developed expertise in animal models of liver diseases, hemodynamic studies, and hepatic cell culture systems. His research contributions have advanced understanding of non-alcoholic and alcoholic fatty liver diseases, hepatopulmonary and porto-pulmonary hypertension, and liver regeneration mechanisms. He has co-authored seven peer-reviewed publications in high-impact journals, including Journal of Hepatology, JHEP Reports, American Journal of Physiology–Gastrointestinal and Liver Physiology, npj Gut and Liver, ACS Omega, and Life Sciences. His work has collectively received 31 citations, 7 Documents, with an h-index of 3, reflecting growing recognition within the biomedical research community. In addition to journal articles, Mr. Akash Mourya has contributed two book chapters published by Springer Nature (2024) and Academic Press (2025), covering topics such as oxidative stress and pharmacological interventions in liver disease, and PPARγ signaling in diabetes. His research abstracts have been presented at prestigious international conferences, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). His work integrates pharmacological innovation, molecular biology, and experimental therapeutics, with emphasis on Ayurvedic formulations, CB2 receptor agonists, and novel siRNA nanoparticle delivery systems. Mr. Akash Mourya’s ongoing efforts contribute to translational R&D for liver protection and regeneration, aligning with India’s growing emphasis on integrative pharmacology and precision medicine.

Profiles: Scopus | Google Scholar | ResearchGate | PubMed 

Featured Publications

1. Baweja, S., Kumari, A., Negi, P., Tomar, A., Tripathi, D. M., Mourya, A. K., Rastogi, A., Subudhi, P. D., Thangariyal, S., Kumar, G., Kumar, J., Sood, A., Vashistha, C., Bihari, C., Maiwall, R., & Sarin, S. K. (2023). Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod. Journal of Hepatology, 79(1), 167–180.

2. Juneja, P., Rahman, S. N. R., Jakhar, D., Mourya, A. K., Tripathi, D. M., Kaur, I., Tiwari, V., & others. (2023). Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis. JHEP Reports, 5(10), 100816.

3. Biswas, S., Yadav, N., Juneja, P., Mourya, A. K., Kaur, S., Tripathi, D. M., & Chauhan, V. S. (2022). Conformationally restricted dipeptide-based nanoparticles for delivery of siRNA in experimental liver cirrhosis. ACS Omega, 7(41), 36811–36824.

4. Kaur, I., Juneja, P., Tiwari, R., Vasudevan, A., Mourya, A. K., Trauner, M., Sarin, S. K., & Tripathi, D. M. (2024). Secondary bile acids in portal blood contribute to liver regeneration in a rat model of partial hepatectomy. American Journal of Physiology – Gastrointestinal and Liver Physiology, 327(4), G645–G658.

5. Tripathi, D. M., Singh, P., Mourya, A. K., & Kaur, S. (2024). Oxidative medicine and novel pharmacological treatment approaches in liver disease. In Adaptation under stressful environments through biological adjustments and interventions (pp. 311–334). Springer Nature.

 

Bing Han | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Dr. Bing Han | Health and Medicine Advances | Best Researcher Award

Postdoctoral Researcher, The First Affiliated Hospital of Zhengzhou University, China

Dr. Bing Han, Professor at The First Affiliated Hospital of Zhengzhou University, China, is an accomplished medical scientist and clinician whose research bridges molecular biology, microbiome science and clinical gastroenterology. He earned his medical degree (M.D.) followed by postdoctoral research training focused on digestive disease mechanisms and microbial interactions, establishing a strong foundation in translational and precision medicine. His primary research interests center on the gut microbiota–host interaction, bile acid metabolism, intestinal inflammation and biomarker discovery for digestive disorders, with emerging interests in microbiome-based therapeutic interventions. Over his distinguished career, Dr. Bing Han has held academic and clinical roles at The First Affiliated Hospital of Zhengzhou University and collaborated with The First Affiliated Hospital of the University of Science and Technology of China, contributing to interdisciplinary advancements in medical research. His key scientific contributions include innovative studies on the mechanisms of fecal microbiota transplantation in improving inflammatory bowel disease (IBD) and the development of biomedical devices such as spinal positioning systems and femoral defect fixation stents. He has published 9 scientific documents, receiving 50 citations with an h-index of 5 and authored the academic book Frontiers of Tumor Research. Among his notable research supports are the China Postdoctoral Science Foundation Grant, National Natural Science Foundation of China Grant and the Guangxi Natural Science Foundation and Health Commission Projects of Guangxi Zhuang Autonomous Region. His professional engagements include serving as a Young Editorial Board Member for the Journal of Guangxi Medical University and membership in the Digestive Professional Committee of the Chinese Society of Pathophysiology and the Gut Microbiota Branch of the Chinese Society of Biophysics. Through his pioneering research on gut microbiota and digestive pathophysiology, Dr. Bing Han aims to revolutionize clinical diagnostics and therapeutics, promoting global health advancement and innovation in biomedical science.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Han, B., Tang, D., Zhu, H., et al. (2024). Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease. Gut Microbes, 16(1), 2310894.

2. Han, B., Li, C., Meng, H., et al. (2019). Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Bioscience Trends, 13(1), 10–22.

3. Han, B., Tang, D., Lv, X., et al. (2023). Comparative efficacy and safety of combination therapy with infliximab for Crohn’s disease: A systematic review and network meta-analysis. International Journal of Colorectal Disease, 38(1), 82.

4. Han, B., Shao, L., Li, C., et al. (2019). Surgery versus external beam radiation therapy for AJCC stage I hepatocellular carcinoma. Journal of BUON, 24(4), 1390–1401.

5. Han, B., Yao, H., Shao, L., et al. (2018). Selection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry database. Journal of BUON, 23(3), 611–621.

 

Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Ms. Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Student, Sanjivani College of Pharmaceutical Education and Research, Kopargaon (SPPU), India

Ms. Seema Kandalkar is a dedicated pharmaceutical researcher currently serving as an IPR Trainee at Trexo Global Pvt. Ltd, Nashik, and is affiliated with Sanjivani College of Pharmaceutical Education and Research (SPPU). She completed her M. Pharmacy in Pharmaceutics from Sanjivani College of Pharmaceutical Education and Research, Kopargaon, in 2025, following a B. Pharmacy from Pravara Rural Education Society College of Pharmacy (SPPU, 2023). Her research primarily focuses on formulation and development of innovative drug delivery systems, including probiotic and effervescent tablet formulations, with emerging interests in regulatory affairs and intellectual property rights. She has gained significant hands-on experience through her industrial projects and internships at Sci-Tech Efferceuticals (R&D), Sanpras Healthcare Pvt. Ltd., and Reve Pharma, where she honed practical skills in analytical techniques, GMP, stability studies, dissolution testing and drug delivery design. Among her key contributions, she successfully developed and evaluated a probiotic effervescent tablet during her M. Pharmacy project and has disseminated her findings via a review article accepted in Journal of Future Foods (ScienceDirect, IF 7.2), along with poster presentations at international conferences and participation in national-level research competitions. Her work has been recognized for its academic rigor and innovative approach in pharmaceutical sciences, earning accolades through national seminars and competitive workshops. Professionally, she is skilled in Microsoft Office Suite, BioRender and Zotero and actively participates in scientific workshops and seminars. Author metrics for Ms. Seema Kandalkar include 1 published document with citation potential, currently reflecting initial scholarly impact. Her work contributes to advancing formulation science, promoting effective healthcare solutions, and strengthening pharmaceutical innovation and intellectual property awareness. Her vision encompasses enhancing patient-centric drug delivery, fostering regulatory excellence and contributing to global pharmaceutical research standards. With her blend of academic excellence, industrial exposure and research innovation, Ms. Seema Kandalkar is well-positioned to make significant contributions to pharmaceutical sciences and healthcare innovation internationally.

Profile: ORCID | ResearchGate | LinkedIn

Featured Publications

1. Kandalkar, S. T., Shendge, R. S., & Lohakare, O. K. (2025). Unveiling the therapeutic potential of probiotics: A review. Journal of Future Foods. Advance online publication.

 

Jie Wu | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Dr. Jie Wu | Health and Medicine | Best Researcher Award

Professor and Lab Director, Shantou University Medical College, China

Prof. Dr. Jie Wu is a Distinguished Professor and Director of the Laboratory of Brain Function and Disease at Shantou University Medical College, China, and formerly served as Professor and Director of the Neurophysiology Laboratory at the Barrow Neurological Institute (BNI), St. Joseph’s Hospital and Medical Center, USA. He earned his M.D. from Xuzhou Medical College in 1983 and Ph.D. in Neurophysiology from Sun Yat-sen University of Medical Sciences in 1990, followed by postdoctoral fellowships at Tohoku University School of Medicine, Japan (1993–1994), and the University of New Mexico, USA (1994–1997). His research focuses on the physiology and pharmacology of nicotinic acetylcholine receptors (nAChRs), molecular mechanisms of epilepsy, and neurodegenerative disorders related to amyloid beta (Aβ) and receptor dysfunction, as well as ATP-sensitive potassium (KATP) channel regulation. Over three decades, he has led groundbreaking neuroscience research funded by the U.S. National Institutes of Health (NIH), the State of Arizona, and various international foundations, making fundamental discoveries in synaptic receptor signaling and neurodegeneration. His pioneering contributions have led to nearly 200 peer-reviewed publications, five book chapters, and eight patents (four U.S. and four Chinese), providing novel insights into receptor-mediated neurological diseases and translational therapies. Among his many honors, Prof. Dr. Jie Wu has received the China National Natural Science Award and the International HH Rosenfield Rekate Pioneer Award, and was listed among the World’s Top 2% Scientists (2022) and elected as a Fellow of the Royal Society of Arts (FRSA, UK, 2024). He serves as Editor-in-Chief and editorial board member for leading international journals and is active in global neuroscience and biomedical societies. With 161 documents, 5,887 citations and an h-index of 44, Prof. Dr. Jie Wu exemplifies research excellence and leadership, advancing global neuroscience through innovation, collaboration, and mentorship that continues to shape the future of brain science and human health worldwide.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | Sci Profiles | Loop | LONGDOM | LinkedIn 

Featured Publications

1. Zhang, X. X., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., Gardner, E. L., & Wu, J. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 111(46), E5007–E5015.

2. Liu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., & Wu, J. (2009). A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. Journal of Neuroscience, 29(4), 918–929.

3. Wang, T. N., Yang, W., Wang, Y., Nagaraj, V. J., Liu, Q., & Wu, J. (2012). Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. Nature Chemistry, 4(10), 846–853.

4. Chen, D. J., Gao, M., Gao, F. F., Su, Q. X., & Wu, J. (2017). Brain cannabinoid receptor 2: Expression, function and modulation. Acta Pharmacologica Sinica, 38(3), 312–316.

5. Okada, Y. C., Wu, J., & Kyuhou, S. (1997). Genesis of MEG signals in a mammalian CNS structure. Electroencephalography and Clinical Neurophysiology, 103(4), 474–485.

 

Yiling Hou | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Dr. Yiling Hou | Health and Medicine | Best Researcher Award

Professor, China West Normal University, China

Prof. Dr. Yiling Hou is a distinguished scientist and Professor at the College of Life Sciences, China West Normal University, recognized as a reserve candidate for academic and technological leadership in Sichuan Province and an overseas high-level talent. She earned her Bachelor of Science in Pharmacy (2005) and Master of Science in Medicinal Chemistry (2008) from Sichuan University, followed by a Doctor of Science in Biochemistry and Molecular Biology (2011) from Sichuan Agricultural University and further enhanced her expertise as a visiting scholar at the Perelman School of Medicine, University of Pennsylvania (2017–2018). Beginning her career as a Teaching Assistant in 2008, she advanced to Lecturer in 2011, Associate Professor in 2011 and full Professor in 2016, also serving as Program Director for Biotechnology (2013–2020) and currently as Deputy Director of the Sichuan Collaborative Innovation Center for Tissue Repair Materials Engineering Technology. Her research focuses on the isolation, purification, structural identification and biological activity of fungal polysaccharides, alongside tumor cell kinetics, spindle dynamics during mitosis, meiosis and the molecular mechanisms underlying cancer progression. Skilled in structural identification, molecular medicine, apoptosis analysis and advanced biopharmaceutical techniques, she has published 104 Scopus-indexed papers with 787 citations and an h-index of 16, reflecting her growing international impact. Prof. Dr. Yiling Hou is an active Councilor of the Sichuan Provincial Microbiology Society and the Sichuan Provincial Youth Federation, highlighting her commitment to scientific community leadership and youth engagement. Honored as an emerging academic leader in Sichuan Province, she continues to guide students and collaborative projects that bridge traditional pharmacology and modern oncology. With her strong publication record, leadership roles and global collaborations, Prof. Dr. Yiling Hou is poised to make transformative contributions to cancer research and molecular therapeutics, advancing biomedical science and inspiring future generations of researchers.

Profile: Scopus | ResearchGate | Sci Profiles | Scilit

Featured Publications

1. Wang, Y., Lu, R., Ding, X., You, Y., Lin, Y., Hou, Y., & Xia, Y. (2025). Structure identification and in vitro immunomodulatory activities of polysaccharide AHL26-P from Arachis hypogaea (Tianfu 26) leaves. Results in Chemistry, 18, 102724.

2. Sun, Z.-A., Zhao, N., Zheng, L., Pan, F., Ding, X., & Hou, Y. (2025, June 26). Comparative studies on the structure and biological activities of two new polysaccharides from Tricholoma flavovirens (TF-P) and Trametes versicolor (TV-P). Results in Chemistry. Advance online publication.

3. Liu, K., Sun, Z., Li, X., Qing, X., Yu, W., Liu, M., Ding, X., & Hou, Y. (2025). Structure characterization and biological activity of polysaccharides from Trametes sanguinea (TS-P) and wild Lentinus edodes (LE-P). Food Bioscience, 68, 106656.

4. Zhou, L., Ding, X., & Hou, Y. (2024). The structure characterization and biological activities of new polysaccharides from Armillariella tabescens (AT-P) and Tricholoma portentosum (TP-P). Results in Chemistry, 18, 4620–4633.

5. Yu, W., Yuan, R., Liu, M., Liu, K., Ding, X., & Hou, Y. (2024). Effects of rpl1001 gene deletion on cell division of fission yeast and its molecular mechanism. Current Issues in Molecular Biology, 46(3), 2576–2597.

 

Cheikh Sokhna | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Cheikh Sokhna | Health and Medicine | Best Researcher Award

Research Director, Institute of Research for Development (IRD), France

Prof. Cheikh Sokhna is a distinguished medical biologist, malariologist and epidemiologist, serving as Research Director at the Institute of Research for Development (IRD), France, director of the Joint Research Team on Infectious, Neglected and Emerging Diseases in the South (MINES) and Team Leader at the Mediterranean Infection University Hospital Institute in Marseille. He holds a Ph.D. in Biomedical Sciences from Cheikh Anta Diop University of Dakar (UCAD, Senegal) and a Habilitation to Direct Research (HDR) in Infectious and Tropical Diseases from Aix-Marseille University (AMU, France). Over the past 25 years, he has focused on malaria, persistent and emerging infectious diseases in West Africa, leading numerous projects and international collaborations with CNRS, Institut Pasteur and the London School of Hygiene and Tropical Medicine. His professional experience includes leadership roles at Aix-Marseille University, IRD, Institut de Microbiologie de la Méditerranée (CNRS) and multiple Pasteur Network centers, reflecting a strong global research presence. Prof. Cheikh Sokhna has supervised 39 theses, including 13 co-supervised between UCAD and AMU and has produced over 480 indexed articles, 2 book directions, and 13 book chapters, with 336 documented publications, 9,382 citations and an h-index of 48. His research interests include infectious diseases, malaria epidemiology, emerging pathogens and tropical disease control and his skills encompass infectious disease research, international development and large-scale scientific project management. He is the first elected President of the Senegalese Society of Parasitology, Mycology and Entomology (SOSEPAME) and actively promotes public science education through media engagements. Prof. Cheikh Sokhna is highly deserving of recognition for his groundbreaking contributions to infectious disease research, mentorship and global health collaborations, demonstrating strong potential to advance high-impact research, strengthen international partnerships and shape the next generation of biomedical scientists.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | Sci Profiles | LinkedIn | ScholarGPS | AD Scientific Index

Featured Publications

1. Lagier, J. C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., … Raoult, D…etc (2016). Culture of previously uncultured members of the human gut microbiota by culturomics. Nature Microbiology, 1(12), 1045.

2. Trape, J. F., Tall, A., Diagne, N., Ndiath, O., Ly, A. B., Faye, J., Dieye-Ba, F., … Rogier, C…etc (2011). Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: A longitudinal study. The Lancet Infectious Diseases, 11(12), 925–932.

3. Senghor, B., Sokhna, C., Ruimy, R., & Lagier, J. C. (2018). Gut microbiota diversity according to dietary habits and geographical provenance. Human Microbiome Journal, 7, 1–9.

4. Sougoufara, S., Diédhiou, S. M., Doucouré, S., Diagne, N., Sembène, P. M., & Sokhna, C…etc (2014). Biting by Anopheles funestus in broad daylight after use of long-lasting insecticidal nets: A new challenge to malaria elimination. Malaria Journal, 13(1), 125.

5. Mediannikov, O., Fenollar, F., Socolovschi, C., Diatta, G., Bassene, H., Molez, J. F., … Raoult, D…etc (2010). Coxiella burnetii in humans and ticks in rural Senegal. PLoS Neglected Tropical Diseases, 4(4), e654.